GLPG vs MTX Comparison

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of our customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve our customers' manufacturing processes and projects. The majority of revenue comes from the United States.